UFPT UFP Technologies, Inc.

UFP Technologies has seen a powerful run in its share price in recent years, which naturally raises a question for anyone looking at the stock today. Is the current valuation supported by the company’s earnings, or has sentiment moved ahead of the underlying profit stream? Over the past 5 years, UFP Technologies has delivered a total return of about 3.8x, which puts real pressure on the current earnings multiple to carry that track record forward. The business leans heavily on specialized...

Tributary Capital Management released its second-quarter 2026 investor letter for “Multi Cap Core Equity Strategy”. You can download a copy of the letter here. The Tributary Multi Cap Core’s equity allocation underperformed in Q2, returning +12.5% against +15.3% for the S&P 1500 and +15.4% for the Russell 3000. Information Technology was the main driver of […]

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Veracyte, Globus Medical and UFP Technologies are positioned to benefit as GenAI adoption reshapes medical instruments.

Investors need to pay close attention to UFPT stock based on the movements in the options market lately.

On August 3, UFP Technologies (NASDAQ:UFPT) reported second-quarter net income of $20.9 million, up 21.4% from $17.2 million a year earlier, alongside net sales of $174.0 million, a 15.1% jump from $151.2 million. Both figures, along with adjusted earnings per share of $2.92, marked the best quarter in the company’s history. For the six months […]

Feldmann reduced her direct stake by 18%.

UFP Technologies (NASDAQ:UFPT) outlined its strategy to expand through organic growth and acquisitions, emphasizing its role as a contract development and manufacturing organization serving medical-device companies. President and Chief Executive Officer Mitch Rock said the company provides engineer

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

UFP Technologies delivered a calendar second quarter marked by strong, broad-based growth across its MedTech platform, which exceeded Wall Street’s revenue and profit expectations. Management pointed to robust performance in key submarkets such as cardiovascular, infection control, and orthopedics, as well as continued diversification across customer programs. CEO Mitchell Rock, in his first earnings call as chief executive, emphasized that growth this quarter was not tied to any one customer or

Record $2.92 adjusted EPS and 15.1% net sales growth highlight strong MedTech momentum.

UFP Technologies (UFPT) is back in focus after reporting record Q2 2026 results, with sales of $173.96 million and net income of $20.85 million. Both figures were above the prior year’s levels. See our latest analysis for UFP Technologies. The strong Q2 2026 earnings have come alongside a clear pickup in momentum for UFP Technologies, with a 22.61% 90 day share price return and a 19.75% year to date share price return, while the 5 year total shareholder return of 319.98% points to substantial...

UFP Technologies easily surpassed Wall Street's expectations and continued to deliver double-digit sales growth.

UFP Technologies (NASDAQ:UFPT) reported second-quarter 2026 sales growth of 15.1% to $174 million, supported by broad-based demand across its medical technology portfolio, while adjusted earnings per share rose 16.8% to a company-record $2.92. President and Chief Executive Officer Mitch Rock, speak

Moby summary of UFP Technologies, Inc.'s Q2 2026 earnings call

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

UFP (UFPT) delivered earnings and revenue surprises of +16.34% and +8.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical products company UFP Technologies (NASDAQ:UFPT) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 15.1% year on year to $174 million. Its non-GAAP profit of $2.92 per share was 14.2% above analysts’ consensus estimates.

Medical products company UFP Technologies (NASDAQ:UFPT) will be reporting results this Monday after market hours. Here’s what you need to know.

Over the past six months, UFP Technologies’s shares (currently trading at $244.72) have posted a disappointing 8.2% loss, well below the S&P 500’s 7.7% gain. This may have investors wondering how to approach the situation.